View Filing Data

Document and Entity Information - USD ($)	12 Months Ended
Document and Entity Information - USD ($)	Dec. 31, 2018	Feb. 28, 2019	Jun. 30, 2018
Document and Entity Information [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2018
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	FY
Entity Registrant Name	Marker Therapeutics, Inc.
Entity Central Index Key	0001094038
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Accelerated Filer
Entity Public Float			$ 81,400,000
Trading Symbol	MRKR
Entity Common Stock, Shares Outstanding		45,467,684
Entity Shell Company	false
Entity Emerging Growth Company	false
Entity Small Business	true

CONSOLIDATED BALANCE SHEETS - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 61,746,748	$ 5,129,289
Prepaid expenses and deposits	141,717	51,150
Interest receivable	108,177	0
Total current assets	61,996,642	5,180,439
Property, plant and equipment, net	147,668	0
Total assets	62,144,310	5,180,439
Current liabilities:
Accounts payable and accrued liabilities	2,754,572	1,513,312
Warrant liability	49,000	9,000
Total current liabilities	2,803,572	1,522,312
Total liabilities	2,803,572	1,522,312
COMMITMENTS AND CONTINGENCIES
Stockholders' equity:
Common stock, $0.001 par value, 150 million shares authorized, 45.4 million and 10.6 million shares issued and outstanding as of December 31, 2018 and 2017, respectively	45,440	10,616
Additional paid-in capital	365,400,748	161,067,538
Accumulated deficit	(306,105,450)	(157,420,027)
Total stockholders' equity	59,340,738	3,658,127
Total liabilities and stockholders' equity	62,144,310	5,180,439
Series A Preferred Stock [Member]
Stockholders' equity:
Preferred Stock, Value	0	0
Series B Preferred Stock [Member]
Stockholders' equity:
Preferred Stock, Value	$ 0	$ 0

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Dec. 31, 2018	Dec. 31, 2017
Preferred stock par value	$ 0.001	$ 0.001
Preferred stock shares authorized/designated	5,000,000	5,000,000
Common stock shares par value	$ 0.001	$ 0.001
Common stock shares authorized	150,000,000	150,000,000
Common stock shares issued	45,400,000	10,600,000
Common stock shares outstanding	45,400,000	10,600,000
Series A Preferred Stock [Member]
Preferred stock par value	$ 0.001	$ 0.001
Preferred stock shares authorized/designated	1,250,000	1,250,000
Preferred stock issued	0	0
Preferred stock outstanding	0	0
Series B Preferred Stock [Member]
Preferred stock par value	$ 0.001	$ 0.001
Preferred stock shares authorized/designated	1,500,000	1,500,000
Preferred stock issued	0	0
Preferred stock outstanding	0	0

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	12 Months Ended
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Revenues:
Total revenues	$ 205,994	$ 183,064
Operating expenses:
Research and development - intellectual property acquired	116,044,886	0
Research and development	7,952,870	5,250,985
General and administrative	24,379,871	6,412,121
Total operating expenses	148,377,627	11,663,106
Loss from operations	(148,171,633)	(11,480,042)
Other income (expense):
Change in fair value of warrant liabilities	(40,000)	5,500
Interest income	253,723	0
Debt extinguishment gain	0	492,365
Net loss	$ (147,957,910)	$ (10,982,177)
Net loss per share, Basic and Diluted	$ (7.75)	$ (1.16)
Weighted average number of common shares outstanding	19,091,926	9,453,483
Grant [Member]
Revenues:
Total revenues	$ 205,994	$ 183,064

CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT) - USD ($)	Total	Common Stock [Member]	Additional Paid- in Capital [Member]	Accumulated Deficit [Member]
Beginning Balance at Dec. 31, 2016	$ 6,184,587	$ 8,421	$ 151,991,974	$ (145,815,808)
Beginning Balance, Shares at Dec. 31, 2016		8,421,185
Issuance of common stock and warrants in private placement	6,190,003	$ 1,504	6,188,499	0
Issuance of common stock in private placement, Shares		1,503,567
Fees and legal costs relating to private placement	(781,660)	$ 0	(781,660)	0
Exercise of warrants	666,666	$ 168	666,498	0
Exercise of warrants, Shares		167,926
Legal costs relating to exercise of warrants	(47,043)	$ 0	(47,043)	0
Fair value of repriced warrants as inducement	0	0	622,042	(622,042)
Stock- based compensation	2,738,244	$ 621	2,737,623	0
Stock- based compensation, Shares		620,685
Repurchase of common stock to pay for employee withholding taxes	(310,493)	$ (98)	(310,395)	0
Repurchase of common stock to pay for employee withholding taxes, Shares		(97,639)
Net loss	(10,982,177)	$ 0	0	(10,982,177)
Ending Balance at Dec. 31, 2017	3,658,127	$ 10,616	161,067,538	(157,420,027)
Ending Balance, Shares at Dec. 31, 2017		10,615,724
Issuance of common stock for research and development intellectual property	116,044,886	$ 13,914	116,030,972	0
Issuance of common stock for research and development intellectual property, Shares		13,914,255
Issuance of common stock and warrants in private placement	73,120,000	$ 18,800	73,101,200	0
Issuance of common stock in private placement, Shares		18,800,000
Fees and legal costs relating to private placement	(6,175,000)	$ 0	(6,175,000)	0
Stock options exercised for cash	18,125	$ 10	18,115	0
Stock options exercised for cash, Shares		10,416
Exercise of warrants	4,353,628	$ 1,499	4,352,129	0
Exercise of warrants, Shares		1,499,324
Fair value of repriced warrants as inducement	0	$ 0	727,513	(727,513)
Stock warrants cashless exercised	0	$ 280	(280)	0
Stock warrants cashless exercised, Shares		280,760
Stock- based compensation	16,350,592	$ 329	16,350,263	0
Stock- based compensation, Shares		327,786
Repurchase of common stock to pay for employee withholding taxes	(71,710)	$ (8)	(71,702)	0
Repurchase of common stock to pay for employee withholding taxes, Shares		(7,561)
Net loss	(147,957,910)	$ 0	0	(147,957,910)
Ending Balance at Dec. 31, 2018	$ 59,340,738	$ 45,440	$ 365,400,748	$ (306,105,450)
Ending Balance, Shares at Dec. 31, 2018		45,440,704

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	12 Months Ended
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Cash Flows from Operating Activities:
Net loss	$ (147,957,910)	$ (10,982,177)
Reconciliation of net loss to net cash used in operating activities:
Changes in fair value of warrant liabilities	40,000	(5,500)
Stock-based compensation	16,350,592	2,738,244
Debt extinguishment gain	0	(492,365)
Research and development - intellectual property acquired	116,044,886	0
Changes in operating assets and liabilities:
Prepaid expenses and deposits	(90,567)	18,999
Interest receivable	(108,177)
Accounts payable and accrued expenses	1,241,260	283,372
Net cash used in operating activities	(14,479,916)	(8,439,427)
Cash Flows from Investing Activities:
Purchase of property and equipment	(147,668)	0
Net cash used in investing activities	(147,668)	0
Cash Flows from Financing Activities:
Proceeds from issuance of common stock and warrants in private placement, net of offering costs	66,945,000	5,408,343
Proceeds from exercise of stock warrants, net of offering costs	4,353,628	619,623
Proceeds from exercise of stock options	18,125	0
Repurchase of common stock to pay for employee withholding taxes	(71,710)	(310,493)
Net cash provided by financing activities	71,245,043	5,717,473
Net increase (decrease) in cash	56,617,459	(2,721,954)
Cash at beginning of year	5,129,289	7,851,243
Cash and cash equivalents at end of year	61,746,748	5,129,289
Supplemental schedule of non-cash financing activities:
Fair value of repriced warrants as inducement	727,513	622,042
Stock warrants cashless exercised	$ 280	$ 0

NATURE OF OPERATIONS

12 Months Ended

Dec. 31, 2018

Organization, Consolidation and Presentation of Financial Statements [Abstract]

NATURE OF OPERATIONS

Note

Nature of Operations

Marker Therapeutics, Inc., a Delaware corporation formerly known as TapImmune, Inc. (the “Company” or “we”), is a clinical-stage immuno-oncology company specializing in the development and commercialization of innovative cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, and novel peptide-based vaccines for the treatment of breast and ovarian cancers. The Company’s cell-based immunotherapy technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens (i.e. tumor targets) and kill tumor cells expressing those targets. Once infused into patients, this population of T cells recognizes multiple tumor targets to produce broad spectrum anti-tumor activity. Because the Company does not genetically engineer its T cells, when compared to current engineered CAR-T and TCR-based approaches, its products (i) are significantly less expensive to manufacture, (ii) appear to be markedly less toxic, and (iii) are associated with potentially meaningful clinical benefit. As a result, the Company believes its portfolio of T cell therapies has a potentially compelling therapeutic product profile, as compared to current gene-modified CAR-T and TCR-based therapies. In addition, the Company’s Folate Receptor Alpha program (TPIV200) for breast and ovarian cancers and our HER2/neu program (TPIV100/110) are in five Phase II clinical trials. In parallel, the Company has been working on a proprietary nucleic acid-based antigen expression technology named PolyStart™ to improve the ability of the immune system to recognize and destroy diseased cells. The Company was incorporated in Nevada in 1992 and reincorporated in Delaware in October 2018 in connection with the Marker Transaction.

On October 17, 2018, the Company completed its previously announced acquisition with Marker Cell Therapy, Inc.,

13,914,255

shares of the Company’s common stock which equaled the number of shares of the Company’s common stock issued and outstanding immediately prior to the effective time of the Merger, and (ii) an aggregate of

5,046,003

warrants which equaled the number of the Company’s warrants and stock options issued and outstanding immediately prior to the effective time of the Merger.

BASIS OF PRESENTATION AND MANAGEMENT PLANS

12 Months Ended

Dec. 31, 2018

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Basis Of Presentation And Management Plans

Note

BASIS OF PRESENTATION AND MANAGEMENT PLANS

The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America. Any reference in these footnotes to applicable guidance is meant to refer to the authoritative U.S. generally accepted accounting principles (“GAAP”) as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”).

The Company has not generated any revenue from product sales to date and, if the Company does not successfully obtain regulatory approval and commercialize any of its product candidates, the Company will not be able to generate product revenue or achieve profitability.

The Company is subject to risks common to companies in the biotechnology industry and the future success of the Company is dependent on its ability to successfully complete the development of, and obtain regulatory approval for its product candidates, manage the growth of the organization, obtain additional financing necessary in order to develop, launch and commercialize its product candidates, and compete successfully with other companies in its industry. These financial statements are presented in United States dollars and have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). In the opinion of management, the accompanying audited consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation of such annual results.

SIGNIFICANT ACCOUNTING POLICIES

12 Months Ended

Dec. 31, 2018

Accounting Policies [Abstract]

SIGNIFICANT ACCOUNTING POLICIES

Note

SIGNIFICANT ACCOUNTING POLICIES

Principles of Consolidation

These financial statements include the accounts of the Company and its wholly-owned subsidiaries, Marker Cell Therapy, Inc. and GeneMax Pharmaceuticals Inc. – a dormant subsidiary that wholly owns GeneMax Pharmaceuticals Canada, Inc. All significant intercompany balances and transactions are eliminated upon consolidation.

Use of Estimates

Preparation of the Company’s financial statements in conformity with GAAP requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ materially from those estimates. Significant areas requiring management’s estimates and assumptions include valuation allowance on deferred tax assets, determining the fair value of stock-based compensation and stock-based transactions, the fair value of the components of the warrant liabilities and accrued liabilities.

Prior Period Reclassification

Prior period grant income that was included in other income (expense) in the December 31, 2017 consolidated statement of operations has been reclassified to revenues for comparability with the December 31, 2018 presentation. This reclassification had no effect on previously reported net loss.

Research and Development – Intellectual Property Acquired

The Company concluded that its acquisition with Marker Cell Therapy, Inc.

completed on October 17, 2018 should be accounted for as an asset acquisition rather than a business combination under Accounting Standards Codification (ASC) 805, Business Combinations. The merger was accounted for as an asset acquisition because substantially all the fair value of the assets being acquired are concentrated in a group of similar assets. Furthermore, the acquired assets did not have outputs or employees. The assets acquired by the Company under the merger included a license, other associated intellectual property, documentation and records, and related materials. Because Marker’s intellectual property had not received regulatory approval, the $116.0 million purchase price paid for these assets was immediately expensed in the Company’s statement of operations as research and development – intellectual property acquired.

Revenue Recognition

The Company has not yet generated any revenue from product sales. The Company’s source of revenue in 2018 and 2017 has been from grants. When grant funds are received after costs have been incurred, the Company records grant revenue upon the receipt of cash.

Cash, Cash Equivalents and Credit Risk

The Company considers highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. Cash and cash equivalents at December 31, 2018 consisted of cash and certificates of deposit in institutions in the United States. Balances at certain institutions have exceeded Federal Deposit Insurance Corporation insured limits and U.S. government agency securities.

The Company maintains cash in accounts which are in excess of the Federal Deposit Insurance Corporation (“FDIC”) insured limits of $250,000. As of December 31, 2018, and 2017, approximately $3.4 million and $4.9 million, respectively, in cash was uninsured based upon the FDIC insurance coverage limits.

Property and Equipment

Leasehold improvements, furniture, equipment and software are recorded at cost and are depreciated using the straight-line method over the estimated useful lives of the related assets, which range from three to five years. Leasehold improvements are amortized over the shorter of the estimated useful life or the remaining lease term.

Rent and Deferred Rent

The Company recognizes rent expense for leases with increasing annual rents on a straight-line basis over the term of the lease. The amount of rent expense in excess of cash payments is classified as deferred rent. Any lease incentives received are deferred and amortized over the term of the lease.

Fair Value Measurements

The Company follows Accounting Standards Codification (“ASC”) 820, “Fair Value Measurements and Disclosures,” (“ASC 820”) for the Company’s financial assets and liabilities that are re-measured and reported at fair value at each reporting period and are re-measured and reported at fair value at least annually using a fair value hierarchy that is broken down into three levels. Level inputs are defined as follows:

Level 1 - Quoted prices (unadjusted) in active markets for identical assets and liabilities.

Level 2 - Inputs other than Level 1 that are observable, either directly or indirectly, such as unadjusted quoted prices for similar assets and liabilities, unadjusted quoted prices in the markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities, financial instruments and concentration of credit risk.

Patents and Patent Application Costs

Although the Company believes that its patents and underlying technology have continuing value, the amount of future benefits to be derived from the patents is uncertain. Patent costs are, therefore, expensed as incurred.

Stock-Based Compensation

The Company incurs stock-based compensation expense related to restricted stock units and stock options. The fair value of restricted stock is determined by the closing market price of the Company's common stock on the date of grant. The Company estimates the fair value of stock options granted using the Black-Scholes option pricing model. The Black-Scholes option pricing model was developed for use in estimating the fair value of traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of highly subjective assumptions, including the expected stock price volatility and expected option life. The Company amortizes the fair value of the awards expected to vest on a straight-line basis over the requisite service period of the awards. Expected volatility is based on historical volatility. The expected life of options granted is based on historical expected life. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant. The forfeiture rate is based on historical data, and the Company records stock-based compensation expense only for those awards that are expected to vest. The dividend yield is based on the fact that no dividends have been paid historically and none are currently expected to be paid in the foreseeable future:

Expected Term

— The expected term of options represents the period that the Company’s stock-based awards are expected to be outstanding based on the simplified method, which is the half-life from vesting to the end of its contractual term.

Expected Volatility

— The Company computes stock price volatility over expected terms based on its historical common stock trading prices.

Risk-Free Interest Rate

— The Company bases the risk-free interest rate on the implied yield available on U. S. Treasury zero-coupon issues with an equivalent remaining term.

Expected Dividend

— The Company has never declared or paid any cash dividends on its common shares and does not plan to pay cash dividends in the foreseeable future, and, therefore, uses an expected dividend yield of zero in its valuation models. The Company recognizes fair value of stock options granted to nonemployees as stock-based compensation expense over the period in which the related services are received.

Research and Development Costs

Research and development expenses consist of expenses incurred in performing research and development activities, including compensation and benefits for research and development employees and consultants, facilities expenses, overhead expenses, cost of laboratory supplies, manufacturing expenses, fees paid to third parties and other outside expenses.

Research and development costs are expensed as incurred. Clinical trial and other development costs incurred by third parties are expensed as the contracted work is performed. The Company accrues for costs incurred as the services are being provided by monitoring the status of the clinical trial or project and the invoices received from its external service providers. The Company estimates depend on the timeliness and accuracy of the data provided by the vendors regarding the status of each project and total project spending. The Company adjusts its accrual as actual costs become known. Where contingent milestone payments are due to third parties under research and development arrangements, the milestone payment obligations are expensed when the milestone events are achieved.

Income Taxes

The Company follows the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of assets and liabilities and their respective tax balances. Potential deferred tax assets and liabilities are measured using enacted tax rates expected to apply to the taxable income in the years in which those differences are expected to be recovered or settled. The effect on potential deferred tax assets and liabilities of a change in tax rates is recognized in the statement of operations in the period that includes the date of allowances against deferred tax assets.

Tax benefits are recognized only for tax positions that are more likely than not to be sustained upon examination by tax authorities. The amount recognized is measured as the largest amount of benefit that is greater than 50 percent likely to be realized upon settlement. A liability for “unrecognized tax benefits” is recorded for any tax benefits claimed in the Company’s tax returns that do not meet these recognition and measurement standards. As of December 31, 2018, and 2017, no liability for unrecognized tax benefits was required to be reported. The guidance also discusses the classification of related interest and penalties on income taxes. The Company’s policy is to record interest and penalties on uncertain tax positions as a component of income tax expense. No interest or penalties were recorded during the years ended December 31, 2018 and 2017.

Warrant Liability

The Company evaluates options, warrants or other contracts to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for. This accounting treatment requires that the carrying amounts of embedded derivatives be marked-to-market at each balance sheet date and carried at fair value. If the fair value is recorded as a liability, the change in fair value during the period is recorded in the Statement of Operations as either income or expense. Upon conversion, exercise or modification to the terms of a derivative instrument, the instrument is marked to fair value at the conversion date and then the related fair value is reclassified to equity.

In circumstances where the embedded conversion option in a convertible instrument is required to be bifurcated and there are also other embedded derivative instruments in the convertible instrument that are required to be bifurcated, the bifurcated derivative instruments are accounted for as a single, compound derivative instrument.

The classification of financial instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. Equity instruments that are initially classified as equity that become subject to reclassification are reclassified to liability at the fair value of the instrument on the reclassification date. Derivative instrument liabilities will be classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument is expected within 12 months of the balance sheet date.

Management must determine whether an instrument (or an embedded feature) is indexed to the Company’s own stock. An entity should use a two-step approach to evaluate whether an equity-linked financial instrument (or embedded feature) is indexed to its own stock, including evaluating the instrument’s contingent exercise and settlement provisions. This exercise affects the accounting for (i) certain freestanding warrants that contain exercise price adjustment features and (ii) convertible notes containing full-ratchet and anti-dilution protections (iii) certain free-standing warrants that contain contingently putable cash settlement.

Grant Income

The Company recognizes grant income in accordance with the terms stipulated under the grant awarded to the Company’s collaborators at the Mayo Foundation from the U. S. Department of Defense. In various situations, the Company receives certain payments from the U.S. Department of Defense for reimbursement of clinical supplies. These payments are non-refundable and are not dependent on the Company’s ongoing future performance. The Company has adopted a policy of recognizing these payments when received and as revenue in accordance with Accounting Standards Update No. 2014-09, “Revenue from Contracts with Customers (Topic 606)” issued by the Financial Accounting Standards Board.

Loss per Common Share

Basic loss per share include only the weighted average common shares outstanding, without consideration of potentially dilutive securities. Diluted loss per share include the weighted average common shares outstanding and any potentially dilutive common stock equivalent shares in the calculation.

New Accounting Standards

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed, we do not believe that the impact of recently issued standards that are not yet effective will have a material impact on our financial position or results of operations upon adoption.

Recent Accounting Standards Adopted in the Year

Revenue from Contracts with Customers

In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers (Topic 606)” (ASU 2014-09) as modified by ASU No. 2015-14, “Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date,” ASU 2016-08, “Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Revenue Gross versus Net),” ASU No. 2016-10, “Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing,” and ASU No. 2016-12, “Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients.” The revenue recognition principle in ASU 2014-09 is that an entity should recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. In addition, new and enhanced disclosures will be required. Companies may adopt the new standard either using the full retrospective approach, a modified retrospective approach with practical expedients, or a cumulative effect upon adoption approach. The Company adopted the new standard effective January 1, 2018, using the modified retrospective approach. The only impact of the adoption of ASU 2014-09 was to reclassify the Company's grant income as revenue.

Recent Accounting Standards Not Yet Adopted

Improvements to Non-Employee Share-Based Payment Accounting

In June 2018, the FASB issued ASU 2018-07 “Improvements to Non-employee Share-Based Payment Accounting”, which simplifies the accounting for share-based payments granted to non-employees for goods and services. Under the ASU, most of the guidance on such payments to non-employees would be aligned with the requirements for share-based payments granted to employees. The amendments are effective for fiscal years beginning after December 15, 2019, and interim periods within fiscal years beginning after December 15, 2020. Early adoption is permitted, but no earlier than an entity’s adoption date of Topic 606. The Company is currently evaluating the impact of the new standard on its consolidated financial statements.

Leases

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) in order to increase transparency and comparability among organizations by, among other provisions, recognizing lease assets and lease liabilities on the balance sheet for those leases classified as operating leases under previous GAAP. For public companies, ASU 2016-02 is effective for fiscal years beginning after December 15, 2018 (including interim periods within those periods) using a modified retrospective approach and early adoption is permitted. In transition, entities may also elect a package of practical expedients that must be applied in its entirety to all leases commencing before the adoption date, unless the lease is modified, and permits entities to not reassess (a) the existence of a lease, (b) lease classification or (c) determination of initial direct costs, as of the adoption date, which effectively allows entities to carryforward accounting conclusions under previous U.S. GAAP. In July 2018, the FASB issued ASU 2018-11, Leases (Topic 842): Targeted Improvements, which provides entities an optional transition method to apply the guidance under Topic 842 as of the adoption date, rather than as of the earliest period presented. The Company adopted Topic 842 on January 1, 2019, using the optional transition method to apply the new guidance as of January 1, 2019, rather than as of the earliest period presented, and elected the package of practical expedients described above. Based on the analysis, the Company expects to recognize additional operating liabilities of approximately $670,000, with corresponding ROU assets of approximately the same amount as of January 1, 2019 based on the present value of the remaining lease payments.

SEC Disclosure Update and Simplification

In August 2018, the SEC adopted the final rule under SEC Release No. 33-10532, Disclosure Update and Simplification, amending certain disclosure requirements that were redundant, duplicative, overlapping, outdated or superseded. In addition, the amendments expanded the disclosure requirements on the analysis of stockholders' equity for interim financial statements. Under the amendments, an analysis of changes in each caption of stockholders' equity presented in the balance sheet must be provided in a note or separate statement. The analysis should present a reconciliation of the beginning balance to the ending balance of each period for which a statement of comprehensive income is required to be filed. This final rule was effective on November 5, 2018. The Company is evaluating the impact of this guidance on its consolidated financial statements. The Company anticipates its first presentation of changes in shareholders’ equity in accordance with the new guidance, will be included in its Form 10-Q for the quarter ended March 31, 2019.

ASSET ACQUISITIONS

12 Months Ended

Dec. 31, 2018

ASSET ACQUISITIONS [Abstract]

Mergers, Acquisitions and Dispositions Disclosures

Note

ASSET ACQUISITIONS

The Asset Acquisition

On October 17, 2018, the Company completed its acquisition with Marker Cell Therapy, Inc.,

formerly known as Marker Therapeutics, Inc., a privately-held Delaware corporation (“Marker Cell”), in accordance with the terms of an Agreement and Plan of Merger and Reorganization dated as of May 15, 2018 (the “Merger Agreement”) by and among the Company, Timberwolf Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of the Company (“Merger Sub”), and Marker. On October 17, 2018, pursuant to the Merger Agreement, Merger Sub was merged with and into Marker Cell (the “Merger”), with Marker Cell being the surviving corporation and becoming a wholly-owned subsidiary of the Company. In connection with the Merger, the Company changed its name to Marker Therapeutics, Inc. and Marker Cell changed its name to Marker Cell Therapy, Inc. At the effective time of the Merger, the former Marker Cell stockholders received (i) an aggregate of 13,914,255 shares of the Company’s common stock which equaled the number of shares of the Company’s common stock issued and outstanding immediately prior to the effective time of the Merger, and (ii) an aggregate of 5,046,003 warrants which equaled the number of the Company’s warrants and stock options issued and outstanding immediately prior to the effective time of the Merger.

Securities Purchase Agreements

On October 17, 2018, concurrent with the completion of the Merger, the Company issued to certain accredited investors in a private placement transaction (the “Financing”), an aggregate of 17,500,000 shares of its common stock, and warrants to purchase 13,437,500 shares of common stock at an exercise price of $5.00 per share with a five-year term, for gross proceeds of $70 million pursuant to the terms of the Securities Purchase Agreements, dated June 8, 2018, by and among the Company and certain accredited investors (the “Securities Purchase Agreements”).

Accounting Treatment

The Company concluded that the merger should be accounted for as an asset acquisition by the Company rather than as a business combination under Accounting Standards Codification (ASC) 805, Business Combinations. The merger was accounted for as an asset acquisition because substantially all the fair value of the assets being acquired are concentrated in a group of similar assets. Furthermore, the acquired assets did not have outputs or employees. The assets acquired by the Company under the merger include a license, other associated intellectual property, documentation and records, and related materials. Because Marker’s intellectual property had not yet received regulatory approval, the $116.0 million purchase price paid for these assets was expensed in the Company’s statement of operations for the fiscal year ended December 31, 2018. The Common Stock issued for the asset acquisition was valued at $116.0 million which is equal to the 13,914,255 common shares issued to Marker multiplied by $8.34, the closing price of the Company’s Common Stock as of October 17, 2018.

The Company also considered whether the merger should be accounted for as a reverse acquisition by Marker. The purpose of the merger is for the Company to acquire the assets of Marker so that the Company can expand its product and service offerings. While the former TapImmune and Marker stockholders hold an equal number of Board seats in the combined entity, the Company concluded that Marker would not be deemed the accounting acquirer under ASC 805, and therefore the merger is not a reverse acquisition.

NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDER

12 Months Ended

Dec. 31, 2018

Noncontrolling Interest [Abstract]

NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDER

Note

NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERS

Net Loss per Share Applicable to Common Stockholders

Basic loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the reporting period. Diluted loss per common share is computed similarly to basic loss per common share except that it reflects the potential dilution that could occur if dilutive securities or other obligations to issue common stock were exercised or converted into common stock.

The following table sets forth the computation of loss per share for the years ended December 31, 2018 and 2017, respectively:

	For the Years Ended
	December 31,
	2018			2017
Numerator:
Net loss	$	(147,957,910	)	$	(10,982,177	)

Denominator:
Weighted average common shares outstanding		19,091,926			9,453,483

Net loss per share data:
Basic and Diluted	$	(7.75	)	$	(1.16	)

The following securities, rounded to the thousand, were not included in the diluted net loss per share calculation because their effect was anti-dilutive for the periods presented:

	For the Years Ended
	December 31,
	2018		2017
Common stock options		4,120,000		489,000
Common stock purchase warrants		22,989,000		6,517,500
Common stock warrants - liability treatment		27,000		3,500
Potentially dilutive securities		27,136,000		7,010,000

PROPERTY AND EQUIPMENT

12 Months Ended

Dec. 31, 2018

Property, Plant and Equipment, Net, by Type [Abstract]

Property, Plant and Equipment Disclosure

Note

PROPERTY AND EQUIPMENT

Property and equipment consist of the following as of December 31, 2018 and 2017, respectively:


		For the years ended December 31,
	Estimated Useful Lives	2018		2017

Computers and equipment	3 - 5 Years	$	66,000	$	-
Office furniture	5 Years		82,000		-
Total		$	148,000	$	-
Less: accumulated depreciation			-		-
Property and equipment, net		$	148,000	$	-

Furniture and computer equipment were placed in use on January 1, 2019, therefore no depreciation expense was recorded during the year ended December 31, 2018.

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

12 Months Ended

Dec. 31, 2018

Payables and Accruals [Abstract]

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

Note

accounts payable and accrued liabilities

Accounts payable and accrued liabilities consist of the following as of December 31, 2018 and 2017, respectively:

	December 31,		December 31,
	2018		2017
Accounts payable	$	1,619,000	$	1,015,000
Compensation and benefits		416,000		162,000
Professional fees		236,000		32,000
Technology license fees		80,000		105,000
Investor relations fees		297,000		110,000
Other		106,000		89,000
Total accounts payable and accrued liabilities	$	2,754,000	$	1,513,000

WARRANT LIABILITY

12 Months Ended

Dec. 31, 2018

Warrant Liability [Abstract]

WARRANT LIABILITY

Note

WARRANT LIABILITY

A weighted average summary of quantitative information with respect to valuation methodology and significant unobservable inputs used for the Company’s common stock purchase warrants that are categorized within Level 3 of the fair value hierarchy for the years ended December 31, 2018 and 2017, respectively:

	Weighted Average Inputs
	For the Years Ended
	December 31,
	2018			2017
Stock price	$	5.55		$	3.92
Exercise price	$	9.72		$	1.20
Contractual term (years)		1.08			0.78
Volatility (annual)		99	%		63	%
Risk-free rate		2	%		1	%
Dividend yield (per share)		0	%		0	%

The foregoing assumptions are recalculated every reporting period and are subject to change based primarily on management’s assessment of the probability of the events described occurring. Accordingly, changes to these assessments could materially affect the valuations.

The following table presents changes in Level 3 warrant liabilities, reflected in accrued expenses measured at fair value for the years ended December 31, 2018 and 2017, respectively:

	Warrant
	Liability
Balance - January 1, 2017	$	14,500
Change in fair value of warrant liability		(5,500	)
Balance – December 31, 2017		9,000
Change in fair value of warrant liability		40,000
Balance – December 31, 2018	$	49,000

FAIR VALUE MEASUREMENTS

12 Months Ended

Dec. 31, 2018

Fair Value Disclosures [Abstract]

FAIR VALUE MEASUREMENTS

Note

FAIR VALUE MEASUREMENTS

Financial assets and liabilities measured at fair value on a recurring basis are summarized below and disclosed on the balance sheet under Derivative liability – warrants:

Fair value measured at December 31, 2018

Quoted prices in active

Significant other

Significant

markets

observable inputs

unobservable inputs

Fair value at

(Level 1)

(Level 2)

(Level 3)

December 31, 2018

Warrant liability

49,000

Fair value measured at December 31, 2017

Quoted prices in active

Significant other

Significant

markets

observable inputs

unobservable inputs

Fair value at

(Level 1)

(Level 2)

(Level 3)

December 31, 2017

Warrant liability

9,000

There were no transfers between Level 1, 2 or 3 during the years ended December 31, 2018 and 2017, respectively.

The valuation of warrants is subjective and is affected by changes in inputs to the valuation model including the price per share of common stock, the historical volatility of the stock price, risk-free rates based on U. S. Treasury security yields, the expected term of the warrants and dividend yield. Changes in these assumptions can materially affect the fair value estimate. The Company could ultimately incur amounts to settle the warrant at a cash settlement value that is significantly different than the carrying value of the liability on the financial statements. The Company will continue to classify the fair value of the warrants as a liability until the warrants are exercised, expire, or are amended in a way that would no longer require these warrants to be classified as a liability. Changes in the fair value of the common stock warrants liability are recognized as a component of other income (expense) in the Statements of Operations.

The net cash settlement value at the time of any future transactions, where the Company consolidates or merges with another entity, will depend upon the value of the following inputs at that time: the consideration value per share of the Company’s common stock, the volatility of the Company’s common stock, the remaining term of the warrant from announcement date, the risk-free interest rate based on U. S. Treasury security yields, and the Company’s dividend yield. The warrant requires use of a volatility assumption equal to the greater of 100% and the 100-day volatility function determined as of the trading day immediately following announcement of a Fundamental Transaction.

STOCKHOLDERS' EQUITY

12 Months Ended

Dec. 31, 2018

Stockholders' Equity Note [Abstract]

STOCKHOLDERS' EQUITY

Note

10:

stockholders’ equity

Preferred Stock

The Company has authorized up to 5,000,000 shares of preferred stock, $0.0001 par value per share, for issuance. The preferred stock will have such rights, privileges and restrictions, including voting rights, dividend conversion rights, redemption privileges and liquidation preferences, as shall be determined by the Company’s board of directors upon its issuance. To date, the Company has not issued any preferred shares.

Series A Preferred Stock -

The Company has designated up to 1,250,000 shares of Series A Preferred Stock, $0.0001 par value per share, for issuance. To date, the Company has not issued any Series A preferred shares.

Series B Preferred Stock -

The Company has designated up to 1,500,000 shares of Series B Preferred Stock, $0.0001 par value per share, for issuance. To date, the Company has not issued any Series B preferred shares.

Common Stock

The Company has authorized up to 150,000,000 shares of common stock, $0.0001 par value per share, for issuance. Significant 2018 and 2017 common stock transactions were as follows:

2018 Common Stock Transactions

The Merger

Pursuant to the Merger discussed in Note 4 above, the Company issued 13,914,255 shares of common stock to shareholders of Marker Cell Therapy, Inc. The fair market value of the shares issued pursuant to the asset acquisition was $116.0 million.

Securities Purchase Agreements

Pursuant to the financing discussed in Note 4 above, the Company issued 17,500,000 shares of its common stock to the participating accredited investors. Net proceeds, after transaction offering costs of $6.2 million, were $63.8 million.

Common Stock Purchase Agreement

On May 14, 2018, the Company’s largest stockholder Eastern Capital Limited entered into a Common Stock Purchase Agreement with the Company pursuant to which it purchased 1,300,000 shares of common stock at a price per share of $2.40 providing gross proceeds to the Company of $3.12 million.

Exercise and Repricing of Warrants Held by Existing Institutional Investors

On May 14, 2018, certain institutional holders of outstanding warrants entered into Warrant Exercise Agreements with the Company that provide for an amendment to the exercise price of the warrants being exercised at $2.50 per share. Upon closing of the Warrant Exercise Agreements, such institutional holders immediately exercised warrants for 782,505 shares of common stock providing aggregate proceeds to the Company of approximately $2.0 million.

The fair value relating to the modification of exercise prices on the repriced and exercised warrants was treated as deemed dividend on the statement of stockholders’ equity of $728,000.

	Weighted Average Inputs
	Before			After
	Modification			Modification
Exercise price	$	9.93		$	2.50
Contractual term (years)		2.37			2.37
Volatility (annual)		79	%		79	%
Risk-free rate		1.5	%		1.5	%
Dividend yield (per share)		0	%		0	%

Exercise of Stock Warrants

In addition to the exercise and repricing of warrants discussed above, during the twelve months ended December 31, 2018, certain outstanding warrants were exercised by warrant holders providing aggregate proceeds to the Company of approximately $2.4 million and resulted in the issuance of 716,819 shares of common stock.

Additionally, 280,760 of the stock warrants exercised were exercised on a cashless basis, which resulted in approximately 204,000 of warrant shares being cancelled due to use of cashless exercise provisions.

Exercise of Stock Options

In January 2018, 10,416 shares of common stock were issued pursuant to stock option exercises at an exercise price equal to $1.74 per share.

Consulting Arrangements

During the twelve months ended December 31, 2018, the Company issued 274,012 shares of common stock in connection with consulting agreements. The fair value of the common stock of approximately $1.8 million was recognized as stock-based compensation expense, $1.7 million in general and administrative expenses and $0.1 million in research and development expenses.

2018 Management and Board Compensation

During the twelve months ended December 31, 2018, the Company issued 53,774 shares of common stock in connection with board of director and management agreements. The fair value of the common stock of approximately $0.5 million was recognized as stock-based compensation expense in general and administrative expenses. 7,561 shares of common stock, with a fair value of $0.1 million, were withheld to satisfy certain payroll liabilities, as applicable to an award to a former director.

2017 Common Stock Transactions

June 2017 Private Placement Transaction

On June 26, 2017, the Company completed private placement of units with certain accredited investors. In the private placement transaction, the Company sold 1,503,567 shares of common stock for $3.97 per share and five-year warrants to purchase an equal number of shares of common stock, at an exercise price of $3.97 per share, for $0.125 per warrant, with one common share and one warrant being sold together as a unit for a total of $4.095 per unit. The Company issued and sold an aggregate of 1,503,567 million units for aggregate gross proceeds of $6.2 million. The Company incurred $0.8 million in agency fees and legal costs. In connection with the offering, the Company reduced the exercise price for the warrants to purchase an aggregate of 653,187 shares of common stock issued to investors in the private placement that closed in August 2016 from $6.00 per share to $3.97 per share.

In addition, the Company issued five-year warrants to the placement agent in the offering providing for the purchase of up to 150,357 shares of Company common stock for $3.97 per share.

June 2017 Exercise and Repricing of Warrants Held by Existing Institutional Investors

On June 23, 2017, certain existing institutional shareholders of the Company who hold various outstanding warrants (i.e. C, D, E and F) to purchase Company common stock, entered into warrant repricing and exercise agreements.

Series E repriced and exercised warrants

Approximately 168,000 of Series E warrants were repriced from $15.00 per share to $3.97 per share and exercised immediately for gross proceeds of approximately $0.7 million. Series E warrants to purchase approximately 187,000 shares of Company common stock being reduced from $15.00 per share to $4.50 per share.

Series C, D & F repriced warrants

Additionally, the exercise prices for certain investors of Series C, Series D and Series F warrants were reduced as follows:

	Number of
	Warrant Shares		Pre-reduced		Post-reduced
Series	Repriced		Price		Price
Series C		313,750	$	6.00	$	4.00
Series D		312,500	$	9.00	$	4.00
Series F		292,500	$	7.20	$	4.00

The fair value relating to the modification of exercise prices on the repriced warrants was treated as deemed dividend on the statement of stockholders’ equity of $0.6 million.

	Before			After
	Modification			Modification
Exercise price	$	8.32		$	4.04
Contractual term (years)		3.34			3.34
Volatility (annual)		200	%		200	%
Risk-free rate		2	%		2	%
Dividend yield (per share)		0	%		0	%

2017 Management Compensation

On March 9, 2017, the Company issued 12,761 shares of stock to Dr. Glynn Wilson. The fair value of the common stock of $55,000 was recognized as stock-based compensation in general and administrative expenses. The issuance was based on the closing price or our common stock of $4.31 per share.

On March 9, 2017, the Company issued 5,220 shares of stock to our former Chief Operating Officer. The fair value of the common stock of $22,500 was recognized as stock-based compensation in general and administrative expenses. The issuance was based on the closing price or our common stock of $4.31 per share.

On September 22, 2017, the Company granted Mr. Hoang 250,000 shares of unregistered, fully vested restricted common stock. The Company recorded $0.8 million of stock-based compensation based on the fair value of the common stock at September 22, 2017. 70,289 shares of common stock, with a fair value of $0.2 million, were withheld (at the closing price of the Company's common stock on the NASDAQ Capital Market on September 22, 2017) to satisfy certain payroll liabilities, as applicable to the award.

On September 22, 2017, the Company granted Dr. Wilson 100,000 shares of unregistered, fully vested restricted common stock. The Company recorded $0.3 million of stock-based compensation based on the fair value of the common stock at September 22, 2017. 27,350 shares of common stock, with a fair value of $0.1 million, were withheld (at the closing price of the Company's common stock on the NASDAQ Capital Market on September 22, 2017) to satisfy certain payroll liabilities, as applicable to the award.

Consulting Arrangements

During fiscal 2017, the Company issued 0.2 million shares of common stock as part of consulting agreements. The fair value of the common stock of $0.6 million was recognized as stock-based compensation in general and administrative expenses.

WARRANTS

12 Months Ended

Dec. 31, 2018

Warrants Disclosure [Abstract]

WARRANTS

NOTE 11: WARRANTS

Share Purchase Warrants

A summary of the Company’s share purchase warrants as of December 31, 2018 and 2017, respectively, and changes during the period is presented below:

						Weighted Average
	Number of			Weighted Average		Remaining Contractual		Total Intrinsic
	Warrants			Exercise Price		Life (in years)		Value
Balance - January 1, 2017		5,059,000		$	8.49		3.68	$	1,713,000
Issued		1,654,000			3.97		-		-
Exercised for cash		(168,000	)		15.00		-		-
Expired or cancelled		(25,000	)		30.50		-		-
Balance - December 31, 2017		6,520,000			6.11		3.16		1,739,000
Issued		18,484,000			4.45		-		-
Cashless exercised		(281,000	)		4.03		-		-
Exercised for cash		(1,499,000	)		6.78		-		-
Expired or cancelled		(208,000	)		4.00		-		-
Balance -December 31, 2018		23,016,000		$	4.78		4.29	$	26,066,000

2018 Warrant Transactions

The Merger

Pursuant to the Merger discussed in Note 4 above, the Company issued 5,046,003 stock warrants to shareholders of Marker Cell Therapy, Inc. at an exercise price of $2.99 per share with a five-year term.

Securities Purchase Agreements

Pursuant to the financing discussed in Note 4 above, the Company issued 13,437,500 stock warrants to certain accredited investors at an exercise price of $5.00 per share with a five-year term.

Exercise and Repricing of Warrants Held by Existing Institutional Investors

The fair value relating to the modification of exercise prices on the repriced and exercised warrants was treated as deemed dividend on the statement of stockholders’ equity of $728,000.

	Weighted Average Inputs
	Before			After
	Modification			Modification
Exercise price	$	9.93		$	2.50
Contractual term (years)		2.37			2.37
Volatility (annual)		79	%		79	%
Risk-free rate		1.5	%		1.5	%
Dividend yield (per share)		0	%		0	%

Exercise of Stock Warrants

2017 Warrant Transactions

June 2017 Private Placement Transaction

June 2017 Exercise and Repricing of Warrants Held by Existing Institutional Investors

Series E repriced and exercised warrants

Series C, D & F repriced warrants

Additionally, the exercise prices for certain investors of Series C, Series D and Series F warrants were reduced as follows:

	Number of
	Warrant Shares		Pre-reduced		Post-reduced
Series	Repriced		Price		Price
Series C		313,750	$	6.00	$	4.00
Series D		312,500	$	9.00	$	4.00
Series F		292,500	$	7.20	$	4.00

The fair value relating to the modification of exercise prices on the repriced warrants was treated as deemed dividend on the statement of stockholders’ equity of $0.6 million.

June 2017 Agent Warrants

Pursuant to an agency agreement, dated May 12, 2017, by and between Katalyst Securities LLC and us, Katalyst agreed to act as our placement agent in connection with the June 26, 2017 private placement offering.

Pursuant to the agreement, we agreed to pay to Katalyst: (i) an aggregate cash fee for placement agent and financial advisory services equal to 10% of the gross proceeds of the Offering; (ii) a non-accountable expense allowance in the amount of Seventy Thousand Dollars ($70,000); and (iii) five-year warrants to purchase a number of shares of our common stock equal to 10% of the number of shares sold in the offering. The Katalyst Warrants have the same terms as the private placement warrants issued in the offering. Based on the 1,503,567 shares of common stock sold in the private placement, we issued five-year warrants to Katalyst providing for the purchase of up to 150,357 shares of Company common stock for $3.97 per share.

STOCK OPTION PLANS

12 Months Ended

Dec. 31, 2018

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

STOCK OPTION PLANS

Note

12:

stock OPTION PLANS

Options to Purchase Shares of Common Stock

2014 Stock Omnibus Plan

On March 19, 2014, the Board adopted the 2014 Omnibus Stock Option Plan (“2014 Plan”), which replaced the 2009 Stock Incentive Plan. The 2014 Plan allowed for grants of stock options, restricted shares, stock bonuses and other equity-based awards to employees and non-employee directors of the Company. Awards under the 2014 Plan may be at prices and for terms as determined by the Board of Directors and may have vesting requirements as determined by the Board, provided that the exercise price for any stock option must be at least equal to the fair market value (as defined in the 2014 Plan) of a share of the stock on the grant date. Once granted, the exercise price of an option may not be reduced without the approval of the Company’s stockholders, other than under certain limited circumstances such as a stock split or take any other action with respect to a stock option that would be treated as a repricing under the rules and regulations of the New York Stock Exchange.

The 2014 Plan was amended in February 2015 to provide for grants to consultants, and again in November 2015 to (i) increase the number of shares reserved for issuance under the Plan to 0.6 million shares; (ii) provide the Board and Committee administering the Plan with full discretion on the vesting period for Service-Vesting Awards under the Plan, including the grant of Awards with less than the Minimum Vesting Requirement (as such terms are defined in the Plan), and (iii) provide the Board and Committee administering the Plan with the ability to grant stock bonuses to executive officers.

On August 29, 2017, the 2014 Plan was amended to increase the shares reserved under the Plan to 1.4 million shares, and on October 16, 2018 the 2014 Plan was amended to increase the shares reserved under the Plan to 8.0 million shares. As of December 31, 2018, approximately 3.4 million options are available to be issued from the 2014 Plan.

Stock Options

A summary of the Company’s employee stock option activity is as follows for stock options:

	Number of Shares			Weighted Average Exercise Price		Total Intrinsic Value		Weighted Average Remaining Contractual Life (in years)
Outstanding as of January 1, 2017		430,624		$	7.41	$	39,000		8.9
Granted		40,000			3.88		-		9.4
Exercised		-			-		-		-
Forfeited/expired		(34,827	)		6.71		-		-
Outstanding as of December 31, 2017		435,797			-		42,000		8.1
Granted		2,464,855			8.79		-		9.8
Exercised		(10,416	)		1.74		-		-
Forfeited/expired		(63,226	)		6.00		-		-
Outstanding as of December 31, 2018		2,827,010		$	8.61	$	113,000		9.5
Options vested and exercisable		1,761,567		$	8.75	$	193,000		9.2

A summary of the Company’s non-employee stock option activity is as follows for stock options:

	Number of Shares			Weighted Average Exercise Price		Total Intrinsic Value		Weighted Average Remaining Contractual Life (in years)
Outstanding as of January 1, 2017		3,471		$	14.77	$	-		8.7
Granted		50,000			2.62		-		9.9
Exercised		-			-		-		-
Forfeited/expired		(13	)		120.00		-		-
Outstanding as of December 31, 2017		53,458		$	3.38	$	65,000		9.7
Granted		1,240,000			-		-		9.8
Exercised		-			-		-		-
Forfeited/expired		-			-		-		-
Outstanding as of December 31, 2018		1,293,458		$	8.86	$	179,000		9.7
Options vested and exercisable		53,458		$	3.38	$	147,000		9.7

The Black-Scholes option pricing model is used to estimate the fair value of stock options granted under the Company’s share-based compensation plans. The weighted average assumptions used in calculating the fair values of stock options that were granted during the years ended December 31, 2018, 2017, respectively, were as follows:

	For the Years Ended
	December 31,
	2018			2017
Exercise price	$	8.89		$	3.25
Expected term (years)		10.0			10.0
Expected stock price volatility		200	%		217	%
Risk-free rate of interest		3	%		2	%
Expected dividend rate		0	%		0	%

The following table sets forth stock-based compensation expenses recorded during the respective periods:

	For the Years Ended
	December 31,
	2018		2017
Stock Compensation expenses:
Research and development	$	1,265,000	$	98,000
General and administrative		15,086,000		2,640,000
Total stock compensation expenses	$	16,351,000	$	2,738,000

At December 31, 2018, the total stock-based compensation cost related to unvested awards not yet recognized was $14.7 million. The expected weighted average period compensation costs to be recognized was 2.0 years. Future option grants will impact the compensation expense recognized.

GRANT INCOME

12 Months Ended

Dec. 31, 2018

Grant Income [Abstract]

Grant Income

Note

13:

grant INCOME

During the years ended December 31, 2018 and 2017, the Company received $0.2 million of a grant awarded to Mayo Foundation from the U.S. Department of Defense for the Phase II Clinical Trial of TPIV200. The grant compensated the Company for clinical supplies manufactured and provided by the Company for the clinical study. In accordance with Accounting Standards Update No. 2014-09, “Revenue from Contracts with Customers (Topic 606)” issued by the Financial Accounting Standards Board, the Company recorded the $0.2 million of grant income as revenue.

COMMITMENTS AND CONTINGENCIES

12 Months Ended

Dec. 31, 2018

Commitments and Contingencies Disclosure [Abstract]

COMMITMENTS AND CONTINGENCIES

Note

14:

COMMITMENTS AND CONTINGENCIES

Operating Lease Obligations

The Company was a party to several operating leases as of December 31, 2018, primarily for office space at certain locations.

Aggregate future minimum annual payments under operating leases at December 31, 2018, are as follows:

Year	Operating Leases
2019	$	294,000
2020		234,000
2021		229,000
2022		71,000
2023		3,000
Thereafter		1,000
Total minimum rentals	$	832,000

Total rental expense under the Company’s operating leases was $175,600 and $121,200 for the years ended December 31, 2018 and 2017, respectively.

LEGAL PROCEEDINGS

12 Months Ended

Dec. 31, 2018

Disclosure Text Block Supplement [Abstract]

LEGAL PROCEEDINGS

Note

15:

LEGAL PROCEEDINGS

From time to time, the Company may be party to ordinary, routine litigation incidental to their business. The Company knows of no material, active or pending legal proceedings against the Company, nor is the Company involved as a plaintiff in any material proceeding or pending litigation. There are no proceedings in which any of the Company’s directors, officers or affiliates, or any registered or beneficial shareholder, is an adverse party or has a material interest adverse to the Company’s interest.

RELATED PARTY TRANSACTIONS

12 Months Ended

Dec. 31, 2018

Related Party Disclosure [Abstract]

RELATED PARTY TRANSACTIONS

Note

16:

RELATED PARTY TRANSACTIONS

Payment made to Mr. John Wilson.

In connection with the Merger discussed in Note 4,

Mr. John Wilson, the former CEO of Marker Cell, was to be reimbursed for certain funds he advanced to Marker Cell prior to the closing of the Merger. Following the consummation of the Merger, in connection with the obligation to reimburse Mr. Wilson for such expenses, the Company paid Mr. Wilson $100,000 as part of the transaction expenses the Company incurred. At the effective time of the Merger, and as part of the terms thereof, Mr. Wilson became a director of the Company.

The Baylor

College of Medicine (“BCM”)

Sponsored Research Agreement.

On November 16, 2018,

in furtherance of the BCM License Agreement and as contemplated by the terms thereof, the Company entered in a Sponsored Research Agreement (“SRA”) with BCM, which provided for the conduct of research for the Company by credentialed personnel at Baylor’s Center for Cell and Gene Therapy. The research is to be supervised by the BCM’s Co-Investigators Dr. Vera and Dr. Leen as set forth and named in the SRA. The SRA has a four-year term. Pursuant to the SRA, the Company has agreed to pay BCM up to

$256,272 for years one and two under the SRA with $76,882 paid up front and $153,764

paid in equal monthly installments over two years and a final payment of $25,626 after receipt of the final written report. Payments for years three and four are to be covered by an amendment.

During the year ended December 31, 2018, the Company paid BCM $0 under the SRA as the upfront payment was made in January 2019. Neither Dr. Vera nor Dr. Leen received any of these payments or are entitled to receive any portion of these payments. Dr. Vera and Dr. Leen do however indirectly benefit from such payments in connection with their status as BCM employees.

The Consulting Agreement-Dr. Vera.

On October 19, 2018,

after the closing of the Merger, the Company entered into a consulting agreement with Dr. Juan Vera, a member of the Company’s Board of Directors, to serve as the Company’s Chief Development Officer. The consulting agreement provided for the payment of an annual base consulting fee of

$350,000

for services to the Company, discretionary cash payment by the Company up to a maximum of

35%

of the base consulting fee, and an award of

500,000

stock options. The consulting agreement is terminable by either party upon

30 days

prior written notice. One quarter of the stock options awarded vest on the first anniversary of the award and the remainder vest evenly in equal monthly installments over a three-year period upon the continued performance of consulting services by Dr. Vera over such period. Dr. Vera, an accomplished individual in his field, has another consulting arrangement with parties unrelated to the Company, that have licensed intellectual property from BCM that resulted from his research and development efforts. He may pursue similar arrangements in the future. During the year ended

December 31, 2018, Dr. Vera was paid $60,577 by the Company under his consulting agreement.

INCOME TAXES

12 Months Ended

Dec. 31, 2018

Income Tax Disclosure [Abstract]

INCOME TAXES

NOTE 17: INCOME TAXES

The Company has no income tax expense due to operating losses incurred for the years ended December 31, 2018 and 2017.

The effects of temporary differences that give rise to significant portions of the deferred tax assets as of December 31, 2018 and 2017 are as follows:

	For the years ended
	December 31,
	2018			2017
Deferred tax assets:
Net operating loss carryforward	$	13,596,000		$	9,690,000
Stock-based compensation		5,741,000			1,556,000
License agreements		206,000			223,000
Research and development		406,000			406,000
Charitable contributions		3,000			3,000
		19,952,000			11,878,000
Less: Valuation allowance		(19,952,000	)		(11,878,000	)
Deferred tax assets, net of valuation allowance	$	-		$	-

On December 22, 2017, the U.S. government enacted comprehensive tax legislation commonly referred to as the Tax Cuts and Jobs Act (the “Tax Act”), which makes broad and complex changes to the U.S. tax code. Certain of these changes may be applicable to the Company, including but not limited to, reducing the U.S. federal corporate tax rate from 34 percent to 21 percent, creating a new limitation on deductible interest expense, eliminating the corporate alternative minimum tax (“AMT”), modifying the rules related to uses and limitations of net operating loss carryforwards generated in tax years ending after December 31, 2017, and changing the rules pertaining to the taxation of profits earned abroad. Changes in tax rates and tax laws are accounted for in the period of enactment. The Tax Act reduces the corporate tax rate to 21 percent, effective January 1, 2018.

The Company assesses the likelihood that deferred tax assets will be realized. To the extent that realization is not likely, a valuation allowance is established. Based upon the history of losses, management believes that it is more likely than not that future benefits of deferred tax assets will not be realized and has established a full valuation allowance for the years ended December 31, 2018 and 2017.

The Company decreased the prior period deferred tax asset by $

4.8

million with a corresponding increase in its valuation allowance. This immaterial adjustment related to the reduction in the federal tax rates from

% to

% and had no impact on the prior period financial statements. Consequently, the valuation allowance increased by

$8.1 million as of December 31, 2018. The Company has research and development tax credit carryforwards of $406,000 to offset future federal income taxes. The research and development tax credit carryforwards begin to expire in 2030.

The Company has approximately $57.0 million of federal and $37.3 million of state Net Operating Losses (“NOL”s) that may be available to offset future taxable income, if any. The federal net operating loss carryforwards of $41.6 million, if not utilized, will expire between 2029 and 2037. The federal net operating loss carryforwards of $15.4 million generated in 2018 are subject to an 80% limitation on taxable income, do not expire and will carry forward indefinitely. The state net operating loss carryforwards of $21.8 million, if not utilized, will begin to expire in 2035. The state net operating loss carryforwards of $15.4 million generated in 2

018 are subject to an 80% limitation on taxable income, do not expire and will carry forward indefinitely.

In accordance with Section 382 of the Internal Revenue code, the usage of the Company’s net operating loss carryforwards may be limited in the event of a change in ownership. A full Section 382 analysis has not been prepared and NOLs could be subject to limitation under Section 382.

For the years ended December 31, 2018 and 2017, the expected tax expense (benefit) based on the U. S. federal statutory rate is reconciled with the actual tax provision (benefit) as follows:

	For the years ended
	December 31,					December 31,
	2018					2017
U.S. federal statutory rate	$	(31,071,000	)	21.00	%	$	(3,734,000	)	34.00	%
State taxes, net of federal benefit		(1,383,000	)	0.93	%		(416,000	)	3.79	%
Federal tax rate change		-		0.00	%		6,275,000		-57.14	%
Permanent Differences
- Non-deductible write-off of acquired R&D expenses		24,369,000		-16.47	%		-		0.00	%
- Change in fair value of derivative liabilities		8,000		-0.01	%		(2,000	)	0.02	%
- Other permanent differences		4,000		0.00	%		(161,000	)	1.47	%
Change in valuation allowance		8,073,000		-5.46	%		(1,914,000	)	17.43	%
Other		-		0.00	%		(48,000	)	0.44	%
Income tax provision/(benefit)	$	-		0.00	%	$	-		0.00	%

ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. As of December 31, 2018, and 2017, there were no unrecognized tax benefits. The Company recognizes accrued interest and penalties as income tax expense. No amounts were accrued for the payment of interest and penalties at December 31, 2018 and 2017. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position in the next year.

SIGNIFICANT ACCOUNTING POLICIES (Policies)

12 Months Ended

Dec. 31, 2018

Accounting Policies [Abstract]

Principles of Consolidation

Use of Estimates

Prior Period Reclassification

Research and Development – Intellectual Property Acquired

The Company concluded that its acquisition with Marker Cell Therapy, Inc.

Revenue Recognition

Cash, Cash Equivalents and Credit Risk

Property and Equipment

Rent and Deferred Rent

Fair Value Measurements

Level 1 - Quoted prices (unadjusted) in active markets for identical assets and liabilities.

Patents and Patent Application Costs

Stock-Based Compensation

Expected Term

Expected Volatility

— The Company computes stock price volatility over expected terms based on its historical common stock trading prices.

Risk-Free Interest Rate

— The Company bases the risk-free interest rate on the implied yield available on U. S. Treasury zero-coupon issues with an equivalent remaining term.

Expected Dividend

Research and Development Costs

Income Taxes

Warrant Liability

Grant Income

Earnings (Loss) Per Common Share

Loss per Common Share

New Accounting Standards

Recent Accounting Standards Adopted in the Year

Revenue from Contracts with Customers

Recent Accounting Standards Not Yet Adopted

Improvements to Non-Employee Share-Based Payment Accounting

Leases

SEC Disclosure Update and Simplification

NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERS (Tables)

12 Months Ended

Dec. 31, 2018

Noncontrolling Interest [Abstract]

Schedule of Earnings Per Share, Basic and Diluted

The following table sets forth the computation of loss per share for the years ended December 31, 2018 and 2017, respectively:

	For the Years Ended
	December 31,
	2018			2017
Numerator:
Net loss	$	(147,957,910	)	$	(10,982,177	)

Denominator:
Weighted average common shares outstanding		19,091,926			9,453,483

Net loss per share data:
Basic and Diluted	$	(7.75	)	$	(1.16	)

Net Loss Per Share

The following securities, rounded to the thousand, were not included in the diluted net loss per share calculation because their effect was anti-dilutive for the periods presented:

	For the Years Ended
	December 31,
	2018		2017
Common stock options		4,120,000		489,000
Common stock purchase warrants		22,989,000		6,517,500
Common stock warrants - liability treatment		27,000		3,500
Potentially dilutive securities		27,136,000		7,010,000

PROPERTY AND EQUIPMENT (Tables)

12 Months Ended

Dec. 31, 2018

Property, Plant and Equipment, Net, by Type [Abstract]

Property, Plant and Equipment

Property and equipment consist of the following as of December 31, 2018 and 2017, respectively:


		For the years ended December 31,
	Estimated Useful Lives	2018		2017

Computers and equipment	3 - 5 Years	$	66,000	$	-
Office furniture	5 Years		82,000		-
Total		$	148,000	$	-
Less: accumulated depreciation			-		-
Property and equipment, net		$	148,000	$	-

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables)

12 Months Ended

Dec. 31, 2018

Payables and Accruals [Abstract]

Schedule of Accounts Payable and Accrued Liabilities

Accounts payable and accrued liabilities consist of the following as of December 31, 2018 and 2017, respectively:

	December 31,		December 31,
	2018		2017
Accounts payable	$	1,619,000	$	1,015,000
Compensation and benefits		416,000		162,000
Professional fees		236,000		32,000
Technology license fees		80,000		105,000
Investor relations fees		297,000		110,000
Other		106,000		89,000
Total accounts payable and accrued liabilities	$	2,754,000	$	1,513,000

WARRANT LIABILITY (Tables) - Fair Value, Inputs, Level 3 [Member]

12 Months Ended

Dec. 31, 2018

Warrant Liability [Line Items]

Valuation Methodology

	Weighted Average Inputs
	For the Years Ended
	December 31,
	2018			2017
Stock price	$	5.55		$	3.92
Exercise price	$	9.72		$	1.20
Contractual term (years)		1.08			0.78
Volatility (annual)		99	%		63	%
Risk-free rate		2	%		1	%
Dividend yield (per share)		0	%		0	%

Schedule of Changes in Level 3 Liabilities Measured at Fair Value

The following table presents changes in Level 3 warrant liabilities, reflected in accrued expenses measured at fair value for the years ended December 31, 2018 and 2017, respectively:

	Warrant
	Liability
Balance - January 1, 2017	$	14,500
Change in fair value of warrant liability		(5,500	)
Balance – December 31, 2017		9,000
Change in fair value of warrant liability		40,000
Balance – December 31, 2018	$	49,000

FAIR VALUE MEASUREMENTS (Tables)

12 Months Ended

Dec. 31, 2018

Fair Value Disclosures [Abstract]

Financial Assets And Liabilities Measured At Fair Value On Recurring Basis

Financial assets and liabilities measured at fair value on a recurring basis are summarized below and disclosed on the balance sheet under Derivative liability – warrants:

Fair value measured at December 31, 2018

Quoted prices in active

Significant other

Significant

markets

observable inputs

unobservable inputs

Fair value at

(Level 1)

(Level 2)

(Level 3)

December 31, 2018

Warrant liability

49,000

Fair value measured at December 31, 2017

Quoted prices in active

Significant other

Significant

markets

observable inputs

unobservable inputs

Fair value at

(Level 1)

(Level 2)

(Level 3)

December 31, 2017

Warrant liability

9,000

STOCKHOLDERS' EQUITY (Tables)

12 Months Ended

Dec. 31, 2018

Stockholders Equity [Line Items]

Weighted Average Inputs Valuation Methodology

	Weighted Average Inputs
	Before			After
	Modification			Modification
Exercise price	$	9.93		$	2.50
Contractual term (years)		2.37			2.37
Volatility (annual)		79	%		79	%
Risk-free rate		1.5	%		1.5	%
Dividend yield (per share)		0	%		0	%

Schedule of weighted average valuation methodology

	Before			After
	Modification			Modification
Exercise price	$	8.32		$	4.04
Contractual term (years)		3.34			3.34
Volatility (annual)		200	%		200	%
Risk-free rate		2	%		2	%
Dividend yield (per share)		0	%		0	%

Warrant [Member]

Stockholders Equity [Line Items]

Schedule of warrants exercise prices were reduced

Additionally, the exercise prices for certain investors of Series C, Series D and Series F warrants were reduced as follows:

	Number of
	Warrant Shares		Pre-reduced		Post-reduced
Series	Repriced		Price		Price
Series C		313,750	$	6.00	$	4.00
Series D		312,500	$	9.00	$	4.00
Series F		292,500	$	7.20	$	4.00

WARRANTS (Tables) - Warrant [Member]

12 Months Ended

Dec. 31, 2018

Schedule of share purchase warrants

A summary of the Company’s share purchase warrants as of December 31, 2018 and 2017, respectively, and changes during the period is presented below:

						Weighted Average
	Number of			Weighted Average		Remaining Contractual		Total Intrinsic
	Warrants			Exercise Price		Life (in years)		Value
Balance - January 1, 2017		5,059,000		$	8.49		3.68	$	1,713,000
Issued		1,654,000			3.97		-		-
Exercised for cash		(168,000	)		15.00		-		-
Expired or cancelled		(25,000	)		30.50		-		-
Balance - December 31, 2017		6,520,000			6.11		3.16		1,739,000
Issued		18,484,000			4.45		-		-
Cashless exercised		(281,000	)		4.03		-		-
Exercised for cash		(1,499,000	)		6.78		-		-
Expired or cancelled		(208,000	)		4.00		-		-
Balance -December 31, 2018		23,016,000		$	4.78		4.29	$	26,066,000

Valuation Methodology

	Weighted Average Inputs
	Before			After
	Modification			Modification
Exercise price	$	9.93		$	2.50
Contractual term (years)		2.37			2.37
Volatility (annual)		79	%		79	%
Risk-free rate		1.5	%		1.5	%
Dividend yield (per share)		0	%		0	%

Schedule of warrants exercise prices were reduced

Additionally, the exercise prices for certain investors of Series C, Series D and Series F warrants were reduced as follows:

	Number of
	Warrant Shares		Pre-reduced		Post-reduced
Series	Repriced		Price		Price
Series C		313,750	$	6.00	$	4.00
Series D		312,500	$	9.00	$	4.00
Series F		292,500	$	7.20	$	4.00

STOCK OPTION PLANS (Tables)

12 Months Ended

Dec. 31, 2018

Schedule or Description of Weighted Average Discount Rate

	For the Years Ended
	December 31,
	2018			2017
Exercise price	$	8.89		$	3.25
Expected term (years)		10.0			10.0
Expected stock price volatility		200	%		217	%
Risk-free rate of interest		3	%		2	%
Expected dividend rate		0	%		0	%

Stock based Compensation Expenses

The following table sets forth stock-based compensation expenses recorded during the respective periods:

	For the Years Ended
	December 31,
	2018		2017
Stock Compensation expenses:
Research and development	$	1,265,000	$	98,000
General and administrative		15,086,000		2,640,000
Total stock compensation expenses	$	16,351,000	$	2,738,000

Employee Stock Option [Member]

Schedule of Share-based Compensation, Nonemployee Director Stock Award Plan, Activity

A summary of the Company’s employee stock option activity is as follows for stock options:

	Number of Shares			Weighted Average Exercise Price		Total Intrinsic Value		Weighted Average Remaining Contractual Life (in years)
Outstanding as of January 1, 2017		430,624		$	7.41	$	39,000		8.9
Granted		40,000			3.88		-		9.4
Exercised		-			-		-		-
Forfeited/expired		(34,827	)		6.71		-		-
Outstanding as of December 31, 2017		435,797			-		42,000		8.1
Granted		2,464,855			8.79		-		9.8
Exercised		(10,416	)		1.74		-		-
Forfeited/expired		(63,226	)		6.00		-		-
Outstanding as of December 31, 2018		2,827,010		$	8.61	$	113,000		9.5
Options vested and exercisable		1,761,567		$	8.75	$	193,000		9.2

Non Employee Stock Option [Member]

Schedule of Share-based Compensation, Nonemployee Director Stock Award Plan, Activity

A summary of the Company’s non-employee stock option activity is as follows for stock options:

	Number of Shares			Weighted Average Exercise Price		Total Intrinsic Value		Weighted Average Remaining Contractual Life (in years)
Outstanding as of January 1, 2017		3,471		$	14.77	$	-		8.7
Granted		50,000			2.62		-		9.9
Exercised		-			-		-		-
Forfeited/expired		(13	)		120.00		-		-
Outstanding as of December 31, 2017		53,458		$	3.38	$	65,000		9.7
Granted		1,240,000			-		-		9.8
Exercised		-			-		-		-
Forfeited/expired		-			-		-		-
Outstanding as of December 31, 2018		1,293,458		$	8.86	$	179,000		9.7
Options vested and exercisable		53,458		$	3.38	$	147,000		9.7

COMMITMENTS AND CONTINGENCIES (Tables)

12 Months Ended

Dec. 31, 2018

Commitments and Contingencies Disclosure [Abstract]

Schedule of Future Minimum Rental Payments for Operating Leases

Aggregate future minimum annual payments under operating leases at December 31, 2018, are as follows:

Year	Operating Leases
2019	$	294,000
2020		234,000
2021		229,000
2022		71,000
2023		3,000
Thereafter		1,000
Total minimum rentals	$	832,000

INCOME TAXES (Tables)

12 Months Ended

Dec. 31, 2018

Income Tax Disclosure [Abstract]

Schedule of Deferred Tax Assets and Liabilities

The effects of temporary differences that give rise to significant portions of the deferred tax assets as of December 31, 2018 and 2017 are as follows:

	For the years ended
	December 31,
	2018			2017
Deferred tax assets:
Net operating loss carryforward	$	13,596,000		$	9,690,000
Stock-based compensation		5,741,000			1,556,000
License agreements		206,000			223,000
Research and development		406,000			406,000
Charitable contributions		3,000			3,000
		19,952,000			11,878,000
Less: Valuation allowance		(19,952,000	)		(11,878,000	)
Deferred tax assets, net of valuation allowance	$	-		$	-

Summary Of Expected Tax Expense Benefit Based On Federal Statutory Rates Reconciled With Actual Tax Provision Benefit

For the years ended December 31, 2018 and 2017, the expected tax expense (benefit) based on the U. S. federal statutory rate is reconciled with the actual tax provision (benefit) as follows:

	For the years ended
	December 31,					December 31,
	2018					2017
U.S. federal statutory rate	$	(31,071,000	)	21.00	%	$	(3,734,000	)	34.00	%
State taxes, net of federal benefit		(1,383,000	)	0.93	%		(416,000	)	3.79	%
Federal tax rate change		-		0.00	%		6,275,000		-57.14	%
Permanent Differences
- Non-deductible write-off of acquired R&D expenses		24,369,000		-16.47	%		-		0.00	%
- Change in fair value of derivative liabilities		8,000		-0.01	%		(2,000	)	0.02	%
- Other permanent differences		4,000		0.00	%		(161,000	)	1.47	%
Change in valuation allowance		8,073,000		-5.46	%		(1,914,000	)	17.43	%
Other		-		0.00	%		(48,000	)	0.44	%
Income tax provision/(benefit)	$	-		0.00	%	$	-		0.00	%

NATURE OF OPERATIONS - Additional Information (Detail) - Marker Therapeutics Inc [Member] - shares	1 Months Ended
	Oct. 17, 2018	Oct. 17, 2018
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares	13,914,255	13,914,255
Warrant [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares	5,046,003	5,046,003

SIGNIFICANT ACCOUNTING POLICIES- Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Jan. 02, 2019
Cash, FDIC Insured Amount	$ 250,000
Cash, Uninsured Amount	3,400,000	$ 4,900,000
Research and Development in Process	$ 116,044,886	$ 0
Property, Plant and Equipment, Estimated Useful Lives	the straight-line method over the estimated useful lives of the related assets, which range from three to five years<table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
Subsequent Event [Member]
Operating Lease, Liability			$ 670,000

ASSET ACQUISITIONS - Additional Information (Detail) - USD ($)	1 Months Ended		12 Months Ended
	Oct. 17, 2018	Oct. 17, 2018	Dec. 31, 2018	Dec. 31, 2017	May 14, 2018	Jun. 26, 2017	Jun. 23, 2017	Aug. 31, 2016
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			716,819		782,505
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 2.50		$ 15.00
Research and Development in Process			$ 116,044,886	$ 0
Stock Issued During Period, Value, Acquisitions			$ 116,044,886
Sale of Stock, Price Per Share	$ 8.34	$ 8.34
Private Placement [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights						653,187
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 3.97	$ 3.97		$ 3.97		$ 6.00
Securities Purchase Agreements [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares			13,437,500
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	13,437,500	13,437,500
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 5.00	$ 5.00	$ 5.00
Research and Development in Process			$ 116,000,000
Sale of Stock, Consideration Received Per Transaction	$ 70,000,000
Class of Warrant or Right Term of Warrants	5 years
Stock Issued During Period, Value, Acquisitions	$ 116,000,000
Stock Issued During Period, Shares, Acquisitions	13,914,255
Securities Purchase Agreements [Member] \| Private Placement [Member]
Sale of Stock, Number of Shares Issued in Transaction	17,500,000
Marker Therapeutics Inc [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares	13,914,255	13,914,255
Stock Issued During Period, Shares, Acquisitions	13,914,255
Marker Therapeutics Inc [Member] \| Warrant [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares	5,046,003	5,046,003

NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERS - Computation of income (loss) per share (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Numerator:
Net loss	$ (147,957,910)	$ (10,982,177)
Denominator:
Weighted average common shares outstanding	19,091,926	9,453,483
Net loss per share data:
Basic and Diluted	$ (7.75)	$ (1.16)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERS - Potentially Dilutive Securities (Detail) - shares	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Potentially dilutive securities	27,136,000	7,010,000
Employee Stock Option [Member]
Potentially dilutive securities	4,120,000	489,000
Warrant [Member]
Common Stock Purchase Warrants	22,989,000	6,517,500
Common Stock Warrants Liability Treatment [Member]
Common Stock Purchase Warrants	27,000	3,500

PROPERTY AND EQUIPMENT - Property and equipment (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 148,000	$ 0
Less: accumulated depreciation	0	0
Property, plant and equipment, net	147,668	0
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 66,000	0
Computer Equipment [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years
Computer Equipment [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 82,000	$ 0
Property, Plant and Equipment, Useful Life	5 years

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES - Accounts payable and accrued liabilities (Detail) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Accounts Payable And Accrued Liabilities [Line Items]
Accounts payable	$ 1,619,000	$ 1,015,000
Compensation and benefits	416,000	162,000
Professional fees	236,000	32,000
Technology license fees	80,000	105,000
Investor relations fees	297,000	110,000
Other	106,000	89,000
Total accounts payable and accrued liabilities	$ 2,754,572	$ 1,513,312

WARRANT LIABILITY - Conversion Option - Valuation Methodology (Detail) - Share Purchase Warrants [Member] - $ / shares	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Stock price	$ 5.55	$ 3.92
Exercise price	$ 9.72	$ 1.20
Contractual term (years)	1 year 29 days	9 months 11 days
Volatility (annual)	99.00%	63.00%
Risk-free rate	2.00%	1.00%
Dividend yield (per share)	0.00%	0.00%

WARRANT LIABILITY - Conversion Option - Schedule of Changes in Level 3 Liabilities Reflected in Accrued Expenses Measured at Fair Value (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Class of Warrant or Right [Line Items]
Balance	$ 9,000	$ 14,500
Change in fair value of warrant liability	40,000	(5,500)
Balance	$ 49,000	$ 9,000

FAIR VALUE MEASUREMENTS - Conversion Option - Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Detail) - Fair Value [Member] - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Derivatives, Fair Value [Line Items]
Warrant liability	$ 49,000	$ 9,000
Quoted prices in active markets (Level 1)
Derivatives, Fair Value [Line Items]
Warrant liability	0	0
Significant other observable inputs (Level 2)
Derivatives, Fair Value [Line Items]
Warrant liability	0	0
Significant other observable inputs (Level 3)
Derivatives, Fair Value [Line Items]
Warrant liability	$ 49,000	$ 9,000

STOCKHOLDERS' EQUITY - Weighted average summary of quantitative information (Detail) - Share Purchase Warrants [Member]	Dec. 31, 2018
Weighted Average Inputs Before Modification [Member] \| Measurement Input, Exercise Price [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Warrants and Rights Outstanding, Measurement Input	9.93
Weighted Average Inputs Before Modification [Member] \| Measurement Input, Expected Term [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Warrants and Rights Outstanding, Term	2 years 4 months 13 days
Weighted Average Inputs Before Modification [Member] \| Measurement Input, Price Volatility [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Warrants and Rights Outstanding, Measurement Input	79
Weighted Average Inputs Before Modification [Member] \| Measurement Input, Risk Free Interest Rate [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Warrants and Rights Outstanding, Measurement Input	1.5
Weighted Average Inputs Before Modification [Member] \| Measurement Input, Expected Dividend Rate [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Warrants and Rights Outstanding, Measurement Input	0
Weighted Average Inputs After Modification [Member] \| Measurement Input, Exercise Price [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Warrants and Rights Outstanding, Measurement Input	2.50
Weighted Average Inputs After Modification [Member] \| Measurement Input, Expected Term [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Warrants and Rights Outstanding, Term	2 years 4 months 13 days
Weighted Average Inputs After Modification [Member] \| Measurement Input, Price Volatility [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Warrants and Rights Outstanding, Measurement Input	79
Weighted Average Inputs After Modification [Member] \| Measurement Input, Risk Free Interest Rate [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Warrants and Rights Outstanding, Measurement Input	1.5
Weighted Average Inputs After Modification [Member] \| Measurement Input, Expected Dividend Rate [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Warrants and Rights Outstanding, Measurement Input	0

STOCKHOLDERS' EQUITY - Summary of number of price-reduced and price-retained warrants (Detail) - $ / shares	Dec. 31, 2018	May 14, 2018	Jun. 23, 2017
Class of Warrant or Right [Line Items]
Price		$ 2.50	$ 15.00
Number of Warrant Shares	716,819	782,505
Number of Warrant Shares Repriced [Member] \| Series C Warrant [Member]
Class of Warrant or Right [Line Items]
Number of Warrant Shares	313,750
Number of Warrant Shares Repriced [Member] \| Series D Warrant [Member]
Class of Warrant or Right [Line Items]
Number of Warrant Shares	312,500
Number of Warrant Shares Repriced [Member] \| Series F Warrant [Member]
Class of Warrant or Right [Line Items]
Number of Warrant Shares	292,500
Pre-reduced Price [Member] \| Series C Warrant [Member]
Class of Warrant or Right [Line Items]
Price	$ 6.00
Pre-reduced Price [Member] \| Series D Warrant [Member]
Class of Warrant or Right [Line Items]
Price	9.00
Pre-reduced Price [Member] \| Series F Warrant [Member]
Class of Warrant or Right [Line Items]
Price	7.20
Post-reduced Price [Member] \| Series C Warrant [Member]
Class of Warrant or Right [Line Items]
Price	4.00
Post-reduced Price [Member] \| Series D Warrant [Member]
Class of Warrant or Right [Line Items]
Price	4.00
Post-reduced Price [Member] \| Series F Warrant [Member]
Class of Warrant or Right [Line Items]
Price	$ 4.00

STOCKHOLDERS' EQUITY - Conversion Option - Valuation Methodology (Detail) - Share Purchase Warrants [Member] - $ / shares	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Exercise price	$ 9.72	$ 1.20
Contractual term (years)	1 year 29 days	9 months 11 days
Volatility (annual)	99.00%	63.00%
Risk-free rate	2.00%	1.00%
Dividend yield (per share)	0.00%	0.00%
Weighted Average Inputs Before Modification [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Exercise price	$ 8.32
Contractual term (years)	3 years 4 months 2 days
Volatility (annual)	200.00%
Risk-free rate	2.00%
Dividend yield (per share)	0.00%
Weighted Average Inputs After Modification [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Exercise price	$ 4.04
Contractual term (years)	3 years 4 months 2 days
Volatility (annual)	200.00%
Risk-free rate	2.00%
Dividend yield (per share)	0.00%

STOCKHOLDERS' EQUITY - Additional Information (Detail)			1 Months Ended					12 Months Ended
STOCKHOLDERS' EQUITY - Additional Information (Detail)	May 14, 2018 USD ($) $ / shares shares	Mar. 09, 2017 USD ($) $ / shares shares	Oct. 17, 2018 USD ($) $ / shares shares	Jan. 31, 2018 $ / shares shares	Sep. 22, 2017 USD ($) shares	Jun. 26, 2017 USD ($) $ / shares $ / PerUnit shares	Jun. 23, 2017 USD ($) $ / shares shares	Dec. 31, 2018 USD ($) $ / shares shares	Dec. 31, 2017 USD ($) $ / shares shares	Aug. 31, 2016 $ / shares
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Common Stock, Par or Stated Value Per Share \| $ / shares								$ 0.001	$ 0.001
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares	$ 2.50						$ 15.00
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	782,505							716,819
Share-based Compensation \| $								$ 16,350,592	$ 2,738,244
Preferred Stock, Shares Authorized								5,000,000	5,000,000
Preferred Stock, Par or Stated Value Per Share \| $ / shares								$ 0.001	$ 0.001
Common Stock, Shares Authorized								150,000,000	150,000,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price \| $ / shares	$ 2.50
Proceeds from Warrant Exercises \| $	$ 2,000,000						$ 700,000	$ 4,353,628	$ 619,623
Class Of Warrant Or Right Warrant Price \| $ / shares						$ 0.125
Exercise Of Warrants Amount \| $								$ 4,353,628	666,666
Number Of Warrants Cancelled due to Cashless Provisions								204,000
Research and Development Expense \| $								$ 7,952,870	5,250,985
Stock Issued During Period, Value, Acquisitions \| $								116,044,886
Non Cash Excercise Of Warrants Amount \| $								280	$ 0
Consulting Arrangements [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Allocated Share-based Compensation Expense \| $								$ 1,800,000
Stock Issued During Period, Shares, New Issues								274,012
Board of Director and Management Agreements [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Stock Issued During Period, Shares, New Issues								53,774
Unissued Common Stock Withheld to Satisfy Payroll Liabilities								7,561
Fair Value of Withheld to Satisfy Certain Payroll Liabilities \| $								$ 100,000
Marker Therapeutics Inc [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Stock Issued During Period, Shares, Acquisitions			13,914,255
Subsequent Warrant Issuance [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares						$ 3.97	$ 3.97
Class of Warrant or Right, Number of Securities Called by Warrants or Rights						150,357	150,357
Class Of Warrant Or Right trancheTwo [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares							$ 4.50
Class Of Warrant Or Right tranche One [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares							$ 15.00
Exercise Of Stock Warrants [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights								716,819
Proceeds from Warrant Exercises \| $								$ 2,400,000
Non Cash Excercise Of Warrants Amount \| $								$ 280,760
Series A Preferred Stock [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Preferred Stock, Shares Authorized								1,250,000	1,250,000
Preferred Stock, Par or Stated Value Per Share \| $ / shares								$ 0.001	$ 0.001
Series B Preferred Stock [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Preferred Stock, Shares Authorized								1,500,000	1,500,000
Preferred Stock, Par or Stated Value Per Share \| $ / shares								$ 0.001	$ 0.001
Warrant [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Exercise Of Warrants Amount \| $								$ 600,000
Common Stock [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period				10,416				10,416
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price \| $ / shares				$ 1.74
Stock Issued During Period, Shares, Share-based Compensation, Gross								327,786	620,685
Exercise Of Warrants Amount \| $								$ 1,499	$ 168
Stock Issued During Period, Value, Acquisitions \| $								$ 13,914
Stock Issued During Period, Shares, Acquisitions								13,914,255
Securities Purchase Agreements [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares			$ 5.00					$ 5.00
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			13,437,500
Stock Issued During Period, Value, Acquisitions \| $			$ 116,000,000
Stock Issued During Period, Shares, Acquisitions			13,914,255
Deferred Offering Costs \| $			$ 6,200,000
Sale of Stock, Consideration Received on Transaction \| $			$ 63,800,000
Common Stock Purchase Agreement [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Proceeds from Issuance of Common Stock \| $	$ 3,120,000
Shares Issued, Price Per Share \| $ / shares	$ 2.40
Sale of Stock, Number of Shares Issued in Transaction	1,300,000
General and Administrative Expense [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Share-based Compensation \| $								$ 15,086,000	$ 2,640,000
General and Administrative Expense [Member] \| Board of Director and Management Agreements [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Allocated Share-based Compensation Expense \| $								$ 500,000
Private Placement [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Common Stock, Par or Stated Value Per Share \| $ / shares										$ 3.97
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares						$ 3.97		$ 3.97	$ 3.97	$ 6.00
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right							168,000
Legal Fees \| $						$ 800,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights						653,187
Number Of Equity Unit Issued						1,503,567
Equity Unit Issued Price Per Unit \| $ / PerUnit						4.095
Aggregate Purchase Price Of Shares Agreed To Purchase Under Stock Purchases Agreement \| $						$ 6,200,000
Proceeds from Warrant Exercises \| $							$ 700,000
Number Of Units Sold						1,503,567	1,503,567
Class Of Warrant Or Right Warrant Price \| $ / shares						$ 0.125
Private Placement [Member] \| Class Of Warrant Or Right tranche One [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right							187,000
Private Placement [Member] \| Series E Warrant [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right							168,000
Private Placement [Member] \| Series E Warrant [Member] \| Maximum [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares							$ 15.00
Private Placement [Member] \| Series E Warrant [Member] \| Minimum [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares							$ 3.97
Private Placement [Member] \| Securities Purchase Agreements [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Sale of Stock, Number of Shares Issued in Transaction			17,500,000
Consulting Agreements [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Fair value of common stock \| $									$ 200,000
Common shares issued									600,000
Research and Development Expense \| $								$ 100,000
Selling, General and Administrative Expense \| $								$ 1,700,000
Chief Executive Officer, President and Chairman [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Stock Issued During Period, Value, Share-based Compensation, Gross \| $		$ 55,000
Share Price \| $ / shares		$ 4.31
Stock Issued During Period, Shares, Share-based Compensation, Gross		12,761
Chief Operating Officer [Member] \| Unregistered Common Stock [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Share-based Compensation \| $					$ 800,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period					250,000
Share Based Compensation Arrangement By Share Based Payment Awards Equity Instruments Other Than Options With held					70,289
Share Based Compensation Arrangement By Share Based Payment Awards Equity Instruments Other Than Options Fair Value Of Instruments With held \| $					$ 200,000
Dr Glynn Wilson [Member] \| Unregistered Common Stock [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Share-based Compensation \| $					$ 300,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period					100,000
Share Based Compensation Arrangement By Share Based Payment Awards Equity Instruments Other Than Options With held					27,350
Share Based Compensation Arrangement By Share Based Payment Awards Equity Instruments Other Than Options Fair Value Of Instruments With held \| $					$ 100,000
President And Chief Operating Officer [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Stock Issued During Period, Value, Share-based Compensation, Gross \| $		$ 22,500
Share Price \| $ / shares		$ 4.31
Stock Issued During Period, Shares, Share-based Compensation, Gross		5,220

WARRANTS - Share Purchase Warrants (Detail) - USD ($)	12 Months Ended
WARRANTS - Share Purchase Warrants (Detail) - USD ($)	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Number of Warrants, Beginning balance	6,520,000	5,059,000
Number of Warrants, Issued	18,484,000	1,654,000
Number of Warrants, Cashless exercised	(281,000)
Number of Warrants, Exercised for cash	(1,499,000)	(168,000)
Number of Warrants, Expired or cancelled	(208,000)	(25,000)
Number of Warrants, Ending balance	23,016,000	6,520,000	5,059,000
Weighted Average Exercise Price, Beginning Balance	$ 6.11	$ 8.49
Weighted Average Exercise Price, Issued	4.45	3.97
Weighted Average Exercise Price, Cashless exercised	4.03
Weighted Average Exercise Price, Exercised for cash	6.78	15.00
Weighted Average Exercise Price, Expired or cancelled	4.00	30.50
Weighted Average Exercise Price, Ending Balance	$ 4.78	$ 6.11	$ 8.49
Weighted Average Remaining Contractual Life, Outstanding (in years)	4 years 3 months 14 days	3 years 1 month 28 days	3 years 8 months 5 days
Weighted Average Remaining Contractual Life, Issued (in years)	0 years	0 years
Total Intrinsic Value, Beginning balance	$ 1,739,000	$ 1,713,000
Total Intrinsic Value, Ending balance	$ 26,066,000	$ 1,739,000	$ 1,713,000

WARRANTS - Weighted average summary of quantitative information (Detail) - Warrant [Member]	Dec. 31, 2018
Weighted Average Inputs Before Modification [Member] \| Measurement Input, Exercise Price [Member]
Warrants and Rights Outstanding, Measurement Input	9.93
Weighted Average Inputs Before Modification [Member] \| Measurement Input, Expected Term [Member]
Warrants and Rights Outstanding, Term	2 years 4 months 13 days
Weighted Average Inputs Before Modification [Member] \| Measurement Input, Price Volatility [Member]
Warrants and Rights Outstanding, Measurement Input	79
Weighted Average Inputs Before Modification [Member] \| Measurement Input, Risk Free Interest Rate [Member]
Warrants and Rights Outstanding, Measurement Input	1.5
Weighted Average Inputs Before Modification [Member] \| Measurement Input, Expected Dividend Rate [Member]
Warrants and Rights Outstanding, Measurement Input	0
Weighted Average Inputs After Modification [Member] \| Measurement Input, Exercise Price [Member]
Warrants and Rights Outstanding, Measurement Input	2.50
Weighted Average Inputs After Modification [Member] \| Measurement Input, Expected Term [Member]
Warrants and Rights Outstanding, Term	2 years 4 months 13 days
Weighted Average Inputs After Modification [Member] \| Measurement Input, Price Volatility [Member]
Warrants and Rights Outstanding, Measurement Input	79
Weighted Average Inputs After Modification [Member] \| Measurement Input, Risk Free Interest Rate [Member]
Warrants and Rights Outstanding, Measurement Input	1.5
Weighted Average Inputs After Modification [Member] \| Measurement Input, Expected Dividend Rate [Member]
Warrants and Rights Outstanding, Measurement Input	0

WARRANTS - Summary of number of price-reduced and price-retained warrants (Detail) - $ / shares	Dec. 31, 2018	May 14, 2018	Jun. 23, 2017
Price		$ 2.50	$ 15.00
Number of Warrant Shares	716,819	782,505
Number of Warrant Shares Repriced [Member] \| Series C Warrant [Member]
Number of Warrant Shares	313,750
Number of Warrant Shares Repriced [Member] \| Series D Warrant [Member]
Number of Warrant Shares	312,500
Number of Warrant Shares Repriced [Member] \| Series F Warrant [Member]
Number of Warrant Shares	292,500
Pre-reduced Price [Member] \| Series C Warrant [Member]
Price	$ 6.00
Pre-reduced Price [Member] \| Series D Warrant [Member]
Price	9.00
Pre-reduced Price [Member] \| Series F Warrant [Member]
Price	7.20
Post-reduced Price [Member] \| Series C Warrant [Member]
Price	4.00
Post-reduced Price [Member] \| Series D Warrant [Member]
Price	4.00
Post-reduced Price [Member] \| Series F Warrant [Member]
Price	$ 4.00

WARRANTS- Additional Information (Detail)			1 Months Ended			12 Months Ended
WARRANTS- Additional Information (Detail)	May 14, 2018 USD ($) $ / shares shares	May 12, 2017 USD ($)	Oct. 17, 2018 $ / shares shares	Jun. 26, 2017 USD ($) $ / shares $ / PerUnit shares	Jun. 23, 2017 USD ($) $ / shares shares	Dec. 31, 2018 USD ($) $ / shares shares	Dec. 31, 2017 USD ($) $ / shares	Aug. 31, 2016 $ / shares
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares	$ 2.50				$ 15.00
Class of Warrant or Right, Number of Securities Called by Warrants or Rights \| shares	782,505					716,819
Common Stock, Par or Stated Value Per Share \| $ / shares						$ 0.001	$ 0.001
Proceeds from Warrant Exercises \| $	$ 2,000,000				$ 700,000	$ 4,353,628	$ 619,623
Class Of Warrant Or Right Warrant Price \| $ / shares				$ 0.125
Exercise Of Warrants Amount \| $						4,353,628	666,666
Stock Issued During Period, Value, Stock Options Exercised \| $	$ 782,505					18,125
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price \| $ / shares	$ 2.50
Proceeds from Issuance of Warrants \| $	$ 2,000,000					2,400,000
Adjustments to Additional Paid in Capital, Warrant Issued \| $						$ 0	$ 0
Warrants and Rights Exercised on CashLess basis \| shares						280,760
Number Of Warrants Cancelled due to Cashless Provisions \| shares						204,000
Warrant [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares						$ 2.99
Class of Warrant or Right Term			5 years
Exercise Of Warrants Amount \| $						$ 600,000
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares \| shares						5,046,003
Private Placement [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares				$ 3.97		$ 3.97	$ 3.97	$ 6.00
Class of Warrant or Right, Number of Securities Called by Warrants or Rights \| shares				653,187
Number Of Equity Units Issued \| shares				1,503,567
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right \| shares					168,000
Common Stock, Par or Stated Value Per Share \| $ / shares								$ 3.97
Legal Fees \| $				$ 800,000
Proceeds from Warrant Exercises \| $					$ 700,000
Class Of Warrant Or Right Warrant Price \| $ / shares				$ 0.125
Equity Unit Issued Price Per Unit \| $ / PerUnit				4.095
Number Of Units Sold \| shares				1,503,567	1,503,567
Aggregate Purchase Price Of Shares Agreed To Purchase Under Stock Purchases Agreement \| $				$ 6,200,000
Percentage of Aggregate Cash Fee for Placement Agent and Financial Advisory Services		10.00%
Non-accountable Expense Allowance \| $		$ 70,000
Warrant [Member]
Exercise Of Warrants Amount \| $						$ 600,000
Adjustments to Additional Paid in Capital, Warrant Issued \| $						$ 728,000
Securities Purchase Agreements [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares			$ 5.00			$ 5.00
Class of Warrant or Right, Number of Securities Called by Warrants or Rights \| shares			13,437,500
Class of Warrant or Right Term			5 years
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares \| shares						13,437,500
Subsequent Warrant Issuance [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares				$ 3.97	$ 3.97
Class of Warrant or Right, Number of Securities Called by Warrants or Rights \| shares				150,357	150,357
Class Of Warrant Or Right trancheTwo [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares					$ 4.50
Class Of Warrant Or Right tranche One [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares					$ 15.00
Class Of Warrant Or Right tranche One [Member] \| Private Placement [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right \| shares					187,000

STOCK OPTION PLANS - Stock Option Activity (Detail) - USD ($)		12 Months Ended
	May 14, 2018	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Number of Shares Outstanding, Ending Balance		3,400,000
Weighted Average Exercise Price per Share, Exercised	$ 2.50
Employee Stock Option [Member]
Number of Shares Outstanding, Begining Balance		435,797	430,624
Number of Shares, Granted		2,464,855	40,000
Number of Shares, Exercised		(10,416)	0
Number of Shares, Forfeited/expired		(63,226)	(34,827)
Number of Shares Outstanding, Ending Balance		2,827,010	435,797	430,624
Number of Shares, Options vested and exercisable		1,761,567
Weighted Average Exercise Price per Share Outstanding, Begining Balance		$ 0	$ 7.41
Weighted Average Exercise Price per Share, Granted		8.79	3.88
Weighted Average Exercise Price per Share, Exercised		1.74	0
Weighted Average Exercise Price per Share, Forfeited/expired		6.00	6.71
Weighted Average Exercise Price per Share Outstanding, Ending Balance		8.61	$ 0	$ 7.41
Weighted Average Exercise Price per Share Exercisable		$ 8.75
Total Intrinsic Value Outstanding		$ 113,000	$ 42,000	$ 39,000
Total Intrinsic Value, Exercisable		$ 193,000
Weighted Average Remaining Contractual Life, Outstanding		9 years 6 months	8 years 1 month 6 days	8 years 10 months 24 days
Weighted Average Remaining Contractual Life, Options granted		9 years 9 months 18 days	9 years 4 months 24 days
Weighted Average Remaining Contractual Life, Exercisable		9 years 2 months 12 days
Non Employee Stock Option [Member]
Number of Shares Outstanding, Begining Balance		53,458	3,471
Number of Shares, Granted		1,240,000	50,000
Number of Shares, Exercised		0	0
Number of Shares, Forfeited/expired		0	(13)
Number of Shares Outstanding, Ending Balance		1,293,458	53,458	3,471
Number of Shares, Options vested and exercisable		53,458
Weighted Average Exercise Price per Share Outstanding, Begining Balance		$ 3.38	$ 14.77
Weighted Average Exercise Price per Share, Granted		0	2.62
Weighted Average Exercise Price per Share, Exercised		0	0
Weighted Average Exercise Price per Share, Forfeited/expired		0	120.00
Weighted Average Exercise Price per Share Outstanding, Ending Balance		8.86	$ 3.38	$ 14.77
Weighted Average Exercise Price per Share Exercisable		$ 3.38
Total Intrinsic Value Outstanding		$ 179,000	$ 65,000	$ 0
Total Intrinsic Value, Exercisable		$ 147,000
Weighted Average Remaining Contractual Life, Outstanding		9 years 8 months 12 days	9 years 8 months 12 days	8 years 8 months 12 days
Weighted Average Remaining Contractual Life, Options granted		9 years 9 months 18 days	9 years 10 months 24 days
Weighted Average Remaining Contractual Life, Exercisable		9 years 8 months 12 days

STOCK OPTION PLANS - Weighted Average Assumptions (Detail) - $ / shares	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Exercise price	$ 8.89	$ 3.25
Expected term (years)	10 years	10 years
Expected stock price volatility	200.00%	217.00%
Risk-free rate of interest	3.00%	2.00%
Expected dividend rate	0.00%	0.00%

STOCK OPTION PLANS - Stock Based Compensation Expenses (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Share-based Compensation	$ 16,350,592	$ 2,738,244
Research and Development Expense [Member]
Share-based Compensation	1,265,000	98,000
General and Administrative Expense [Member]
Share-based Compensation	$ 15,086,000	$ 2,640,000

STOCK OPTION PLANS - Additional Information (Detail) - USD ($) shares in Millions, $ in Millions	1 Months Ended	12 Months Ended
	Nov. 30, 2015	Dec. 31, 2018	Oct. 16, 2018	Aug. 29, 2017
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized			8.0	1.4
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number		3.4
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized		$ 14.7
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition		2 years
Omnibus Stock Option Plan 2014 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized	0.6

GRANT INCOME - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Revenues	$ 205,994	$ 183,064
Accounting Standards Update 2014-09 [Member]
Revenues	200,000
Grant [Member]
Revenues	$ 205,994	$ 183,064

COMMITMENTS AND CONTINGENCIES (Details)	Dec. 31, 2018 USD ($)
2019	$ 294,000
2020	234,000
2021	229,000
2022	71,000
2023	3,000
Thereafter	1,000
Total	$ 832,000

COMMITMENTS AND CONTINGENCIES - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Commitments And Contingencies [Line Items]
Operating Leases, Rent Expense, Net	$ 175,600	$ 121,200

RELATED PARTY TRANSACTIONS - Additional Information (Detail) - USD ($)	1 Months Ended		12 Months Ended
	Nov. 16, 2018	Oct. 19, 2018	Dec. 31, 2018
Sponsored Research Agreement Term	4 years
Sponsored Research Fee Payable Due In Year Next Twelve Months			$ 256,272
Sponsored Research Fee Payable Due In Year Two			256,272
Upfront Fees Paid			76,882
Sponsored Research Fee Installment			153,764
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted		500,000
Payment for Sponsored Research Fees			0
BCM [Member]
Sponsor Fees			25,626
Consulting Arrangements [Member]
Consulting Fees		$ 350,000
Consulting Fees Discretionary Cash Payment Percentage		35.00%
Consulting Agreement Termination Term		30 days
Chief Development Officer [Member] \| Consulting Arrangements [Member]
Consulting Fees		$ 60,577
Marker Therapeutics Inc [Member]
Business Acquisition, Transaction Costs			$ 100,000

INCOME TAXES - Summary of Effects of Temporary Differences that Give Rise to Significant Portions of the Deferred Tax Assets (Detail) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Deferred tax assets:
Net operating loss carryforward	$ 13,596,000	$ 9,690,000
Stock-based compensation	5,741,000	1,556,000
License agreements	206,000	223,000
Research and development	406,000	406,000
Charitable contributions	3,000	3,000
Deferred Tax Assets	19,952,000	11,878,000
Valuation allowance	(19,952,000)	(11,878,000)
Deferred tax assets, net of valuation allowance	$ 0	$ 0

INCOME TAXES- Summary of Expected Tax Expense (Benefit) Based on the U.S. Federal Statutory Rate is Reconciled with the Actual Tax Provision (Benefit) (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
U. S. federal statutory rate	$ (31,071,000)	$ (3,734,000)
State taxes, net of federal benefit	(1,383,000)	(416,000)
Federal tax rate change	$ 0	$ 6,275,000
U. S. federal statutory rate, Percent	21.00%	34.00%
State taxes, net of federal benefit, Percent	0.93%	3.79%
Federal tax rate change, Percent	0.00%	(57.14%)
Permanent differences
Permanent differences-- Non-deductible write-off of acquired R&D expenses	$ 24,369,000	$ 0
Permanent differences- Change in fair value of derivative liabilities	8,000	(2,000)
Permanent differences- Other permanent differences	4,000	(161,000)
Change in valuation allowance	8,073,000	(1,914,000)
Other	0	(48,000)
Income tax provision (benefit)	$ 0	$ 0
Permanent differences-- Non-deductible write-off of acquired R&D expenses, Percent	(16.47%)	0.00%
Permanent differences- Change in fair value of derivative liabilities, Pecent	(0.01%)	0.02%
Permanent differences- Other permanent differences, Percent	0.00%	1.47%
Change in valuation allowance, Percent	(5.46%)	17.43%
Other, Percent	0.00%	0.44%
Income tax provision (benefit), Percent	0.00%	0.00%

INCOME TAXES - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Income Tax [Line Items]
Tax credit carryforwards expiration period	2029
Deferred Tax Assets, Tax Credit Carryforwards, Research	$ 406,000	$ 406,000
Tax credit carryforwards expiration year end	2037
Deferred Tax Assets, Operating Loss Carryforwards, Foreign	$ 57,000,000	41,600,000
Deferred Tax Assets, Operating Loss Carryforwards, State and Local	37,300,000	21,800,000
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount	$ (8,073,000)	$ 1,914,000
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	21.00%	34.00%
Operating Loss Carryforwards Limitation Percentage	80.00%
Decreased Deferred Tax Assets		$ 4,800,000
Foreign Tax Authority [Member]
Income Tax [Line Items]
Operating Loss Carryforwards	$ 15,400,000
State and Local Jurisdiction [Member]
Income Tax [Line Items]
Operating Loss Carryforwards	$ 15,400,000